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1.  Abstract 
Introduction: Anti-TNF agents are  a main therapeutic strategy in ulcerative colitis. 
However, the reporting quality of their Randomized Controlled Trials (RCTs) has not 
been yet assessed. 
Objective: This study aims to assess the reporting quality of RCTs on anti-TNF agents 
for ulcerative colitis published from 2005 to 2015, using the CONSORT 
(Consolidated Standards of Reporting Trials) 2010 statement. 
Methods: Pubmed and Cochrane CENTRAL databases were searched in July 2015 for 
relative RCT reports. Each item of the CONSORT 2010 checklist was scored with 1 if 
clearly reported or 0 otherwise. Total CONSORT scores and frequencies of reporting 
each item were calculated. Comparisons between pre- and post-CONSORT 2010 
periods were made with Mann-Whitney and Fisher exact tests. 
Results: The total CONSORT score of the 11 articles, in the combined 2005-2015 
period, ranged from 17 to 31. Items of the CONSORT checklist were reported in 
different frequencies. 10 items were reported in 100% of the articles while 12 were 
reported in less than 50% of the articles. Between the two period groups, a significant 
improvement in reporting objectives (Fisher exact P=0.018) was found. 
Conclusion: Some key methodological items are inadequately reported. To raise the 
reporting quality of RCTs on anti-TNF agents for ulcerative colitis, further 
improvement is needed . 
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Ulcerative colitis is a chronic inflammatory bowel disease of the rectum and colon. It is 
characterized by inflammation restricted in the mucosal layer of the colon that leads to  
formation of ulcers. The disease strikes people of different ages with a peak in the second 
and third decade of life(1, 2).Some studies indicate a second peak around the age of 60 
years old(3, 4). According to the literature, prevalence ranges from 7.6 to 245 cases  per 
100000 persons and the incidence from 1.2 to 20.3 cases per 100000 persons per 
year(1,2). The frequency varies in different regions of the world, being higher in Northern 
America and Northern Europe(4-7). 
 
The disease history has a relapsing-remitting form and  a serious impact on patients’ 
everyday functionality and quality of  life(8-10). Diagnosis is made on the basis of 
clinical presentation, endoscopic pictures and confirmatory biopsies. Clinically ulcerative 
colitis is presented with the following symptoms: diarrhea mixed with blood and mucous, 
abdominal pain, tenesmus and general symptoms such as fever, weight loss and malaise. 
Apart from the bowel symptoms, the disease has also extraintestinal manifestations. 
Erythema nodosum, pyoderma gangrenosum, arthropathies, scleritis of the eye, primary 
sclerosing cholangiitis are some examples(1, 2) 
 
Although the exact pathogenetic mechanisms are not fully known, it is accepted that 
ulcerative colitis has an immune mediator basis. TNFa, one of the most studied pro-
inflammatory cytokines, plays a major role in the whole inflammatory process, as 
identified  15-20 years ago. Elevated TNFa levels were found in intestinal mucosa and 
stool of patients with inflammatory bowel disease, according to some studies(11). 
 
In order to inhibit the TNFa action several biologic agents have been developed and 
studied: the anti-TNF agents. Beside this type of biologic agents, treatment options 
include 5-aminosalicylates (mesalamine, sulfasalazine), corticosteroids, thiopurines 
(azathioprine, mercaptopurine), calcineurine inhibitors (cyclosporine, tacrolimus), other 
biologic agents such as vedolizumab or colectomy in case of complication (perforation, 
megacolon,cancer) or non-response to drug therapy. Anti-TNF agents are used in 
moderate to severe ulcerative colitis and in case that first line  drugs like 5-
aminosalicylates, steroids and thiopurines fail to induce and maintain remission. 
Currently in use are: infliximab, adalimumab and golimumab. All of them are monoclonal 
antibodies against TNFa. Infliximab is chimeric with combined human and murine 
protein parts while the other two are totally humanized having lower immunity(1, 12). 
 
Anti-TNF agents became the last decade a main therapeutic strategy against ulcerative 
colitis after they had proven efficacy, safety and effectiveness through randomized 
clinical trials (RCTs) appropriately designed, properly conducted and clearly reported. 
 
RCTs  are considered as a gold standard in the evaluating process of  new interventions 
through the comparison with standard treatment or placebo. In order to provide strong 
medical evidence, they must lie on strict methodology and should be clearly and 
adequately reported. Randomization, allocation, blinding are some key aspects of the 
value of a trial. Implementation weaknesses and/or poor reporting can mislead to biased 
results affecting health care providers and even health policy makers. Additionally, a 
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complete and transparent RCT report can elucidate any methodological drawbacks of the 
study, revealing its credibility(13-15). 
 
Aiming to improve the reporting quality of RCTs, the CONSORT (Consolidated 
Standards of Reporting Trials) statement was first developed in 1996. Since then it has 
been revised twice, in 2001 and in 2010. The last revision has provided a 25-item 
checklist that every trial should address in its report (see Appendix), and a flow diagram 
describing the subjects flow through the trial procedures. While the CONSORT statement 
can be applied in RCTs in general, it focuses on randomized trials with two parallel arms. 
For other study types and intervention types (herbal medicinal products, acupuncture, 
non-pharmacologic) several CONSORT extensions have been developed. There are also 
CONSORT extensions for harms and abstracts. All these products are accessible through 
the website www.consort-statement.org (13). 
 
Since its appearance, CONSORT statement gains increasing support from more than 400 
medical journals. Even significant editorial groups like International Committee  of 
Medical Journal Editors and the Council of Science Editors endorse it, leading to 
reporting quality improvement(15). 
 
There is a number of published reviews assessing the reporting quality of RCTs in several 
medicinal subspecialties(16-20) and even in hepato-gastroenterology(21). Generally, they 
conclude that there is some improvement through the years but not at an expected level. 
In the field of ulcerative colitis, progress is made in understanding the pathogenetic 
mechanisms and leads to development of new drugs. Thus, novel biologic agents are 
emerging such as the anti-TNF agent AVX-740, etrolizumab, vercirnon, tofacitinib(22). 
As a result more and more RCTs are designed and conducted to evaluate these agents. 
However, the reporting quality of RCTs for anti-TNF agents in ulcerative colitis, so far,  
is not known. This knowledge would contribute to trial replication and to the credibility 
of results of RCTs. Health care providers and policy makers could draw safer conclusions 
evaluating the efficacies of the different agents and designing therapeutic strategies. 
 
In this context, aim of this study is to assess the reporting quality of RCTs for anti-TNF 
agents in ulcerative colitis published from 2005 to 2015. 
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3.1 Search strategy 
Pubmed and Cochrane CENTRAL databases were searched in July 2015 for reports on 
RCTs involving anti-TNF agents in ulcerative colitis. On Pubmed the following search 
terms were used: ‘tnf AND ulcerative colitis’, ‘infliximab AND ulcerative colitis’, 
‘adalimumab AND ulcerative colitis’, ‘golimumab AND ulcerative colitis’. The filters 
‘article type’ and ‘publication date’ were customized as ‘Randomized Controlled Trials’ 
and ‘from 2005/01/01 to 2015/12/31’ respectively. The same search terms were used on 
Cochrane CENTRAL database setting the following search limits: database  as ‘Trials’ 
and publication date as ‘between 2005 and 2015’. 
The initial search conducted for ‘tnf AND ulcerative colitis’ demonstrated  infliximab, 
adalimumab and golimumab as the only relative anti-TNF agents. Thus, taking into 
consideration the literature[12,22,23] as well, it was decided to broaden the search using 
these 3 terms. 
 
 
3.2 Eligibility criteria-study selection 
Type of studies: eligible were only RCTs. To consider a study as RCT, participating 
subjects should have been randomized in at least two arms. Other types of studies such as 
retrospective, animal, genetic association studies were excluded.  
Type of participants: no limitations regarding to age, gender, origin. 
Type of intervention: eligible were studies testing  biologic anti-TNF agents(antibodies 
against TNF). Herbal extracts, food supplements and other types of intervention were set  
as an exclusion criterion. 
Type of disease: RCTs were eligible, if  they clearly stated that the intervention was 
tested only for ulcerative colitis. IBD (Inflammation Bowel Disease) in general or 
Crohn’s disease were also exclusion criteria. 
Type of publication: eligible were only full articles, written in English language, 
published in biomedical journals from 01/01/2005 to the day of search(15/07/2015). 
Abstracts, editorials, reviews, meta-analyses, letters and other type of publication were to 
be excluded from the analysis. 
Post-hoc, subgroup and pharmacokinetic analyses were to be excluded only after reading 
the article, in order not to lose any additional published work,  unidentified with Pubmed 
or Cochrane CENTRAL. 
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From the records identified, duplications and abstracts were removed. Then an initial 
screening was performed on the basis of title and the remaining articles were read in 
abstract and full text to apply the eligibility criteria and select the reports included in the 
analysis. References of the articles included in the analysis were screened in order not to 
lose any relative reports unidentified with the initial search. 
 
3.3 Data extraction and assessment of reporting quality according to 
CONSORT statement 
The selected articles were assessed for reporting quality using the revised CONSORT 
2010 checklist (www.consort-statement.org). This checklist is a questionnaire with 25 
items and totally 37 (sub-)items, evaluating if several aspects of the trial are reported and 
not whether they are  implemented. Following the relevant guidelines(14), each (sub-) 
item for each eligible article was scored separately with 1 or 0. 1 was scored when the 
item was clearly reported in the article. Negative or alternative responses apart from yes 
and no were scored as 0. Thus, a total CONSORT score for each article was obtained with   
maximum probable total CONSORT score being equal to 37. 
 
3.4 Data analysis 
Total CONSORT scores of articles were analyzed initially using descriptive statistics 
methods. Taking into consideration that the revised CONSORT 2010 checklist was first 
introduced in 2010, three period groups were formed: one including articles from 2005 to 
2010, another including articles published from 2010 to 2015 and a combined group, 
taking all articles together. Medians and means were calculated. Pre- and post-CONSORT 
groups were compared in total CONSORT scores to test for significant differences using 
Mann-Whitney U test for 2 independent samples.  
Frequencies for each reporting item of the checklist were calculated for pre- , post-
CONSORT and combined period group of articles. Additionally, it was intended to 
examine whether the reporting quality of trials improved after the introduction of the 
2010 revised version of CONSORT. To achieve that, a Fisher exact test  between the two 
period groups (pre- and post-CONSORT) was to be performed. Due to the small size of 
pre- and post-CONSORT 2010 groups, the Pearson’s chi-square test was  rejected and 
results were interpreted cautiously.  
Categorical data were processed, frequencies were calculated and statistical tests  were 
performed using IBM SPSS v21 statistics package, provided by University of Thessaly. A 
P-value of 0.05 was set as a threshold of statistical significance. 
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4.1 Search results 
230 records were identified searching Pubmed and Cochrane CENTRAL databases. 80 
duplications and 74 abstracts were removed. After that, screening on the remaining 76 
records was performed and 37 were rejected on the basis of title. The 39 reports left were 
assessed for eligibility, reading abstracts and full-text articles. Finally, 11 articles were 
included in the analysis (Figure1). 
 
 
Figure  1.  Flow diagram of the  study selection process 
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4.2 Study characteristics 
6 RCTs were published in Gastroenterology journal, 1 in Ulcers, 1 in New England 
Journal of Medicine, 1 in Gut, 1 in Lancet and 1 in Clinical Gastroenterology and 
Hepatology. There were 2 publications in the pre-CONSORT 2010 period (2005-2010),  
and 9 publications after 2010. Three types of anti-TNF agent, as tested intervention, were 
met: infliximab in 6 reports, adalimumab in 3 reports and golimumab in 2 reports. The 
control group received placebo in 7 RCTs and another  pharmaceutical substance in 4 
RCTs. 5 trials had 2 study arms while 6 trials had more than 2 (3 or 4) study arms. Of the 
RCTs included in the analysis, only 1 was conducted in a single center, 1 was involving 
children and 3 had an open-label design. Characteristics of the trials included in the 
analysis are shown in Table1. 
 
 
Table1.  Characteristics of RCTs included in the analysis 
  Number of RCTs 
Journal Gastroenterology 6 
 Ulcers 1 
 New England Journal of 
Medicine 
1 
 Gut 1 
 Lancet 1 
 Clinical Gastroenterology and 
Hepatology 
1 
Funding sources Pharmaceutical Industries 9 
 Other 2 
Tested intervention Infliximab 6 
 Adalimumab 3 
 Golimumab 2 
Control  Placebo 7 
 Other pharmaceutical substance 4 
RCT arms 2 5 
 >2 6 
Age of participants Adults 10 
 Children 1 
Type of study (center) Single-center 1 
 Multi-center 10 
Blinding Blinded 8 
 Open-label 3 
CONSORT 2010 flow 
diagram 
Disposable 2 
 Not disposable 9 
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4.3 Reporting quality 
The total CONSORT score of  RCTs  reports, included in the  combined period (2005-
2015), ranged from 17 to 31 with a mean of  23 and a median equal to 22 (mean=23, 
SE=1.22,  SD=4.04, median=22). Regarding the pre- and post-CONSORT 2010 period, 
median total CONSORT scores were 23.5 and 22 respectively. No statistically significant 
difference in total CONSORT score between pre- and post-CONSORT 2010 period 
groups was found( P=0.722>0.05 , Mann Whitney U test). The scoring process of the 
articles according to CONSORT 2010 checklist and the total scores are indicated in 
Table2. 
Items of the CONSORT 2010 checklist were reported in different frequencies by the 
articles included in the analysis (Table3). Abstract (Item 1b), Background (Item 2a), 
Eligibility criteria (Item 4a), Sample size calculation (Item 7a), Participant flow (Item 
13a), Baseline data (Item 15), Numbers analysed (Item  16), Harms (Item 19), 
Generalisability (Item 21) and Funding (Item 25) were reported in all of the 11 RCTs. 
None of the articles reported Protocol (Item 24), which indicated where the full protocol 
of the trial could be accessed. Changes to outcomes (Item 6b) were reported in none of 
the 11 articles. 
4 items had a frequency of reporting 90.9% in the combined period 2005-2015. These 
were: settings and locations (Item4b), sufficient description of the interventions and their 
administration (Item5), trial limitations (Item20) and interpretation (Item 22). Specific 
objectives (Item 2b), sufficient description of trial design with allocation ratio (Item3a) 
and definition of primary and secondary outcomes (Item 6a) were reported by 81.8% of 
the articles. The following most reported items, with a proportion of 72.7%, were 
randomization type (Item 8b) and losses and exclusions after randomization with 
justification (Item 13b). 63.6% of the articles reported statistical methods used for 
primary and secondary outcomes (Item 12a), methods for additional analyses (Item 12b) 
and registration number in the trial registry (Item 23). Justified changes to trial methods  
after its start (Item 3b), description of the allocation concealment mechanism with 
sufficient detail (Item 9) and ancillary analyses with a distinction in pre-specified and 
post-hoc (Item 18) were reported in 54.5% of the trials. 
12 items, including Protocol and Changes to outcomes, were reported in less than 50% of 
the studies selected. Recruitment and follow-up periods (Item 14a) had a proportion of 
reporting equal to 36.4%, while only 27.3% of the articles identified the study as RCT 
(Item 1a). Allocation sequence generator (Item 8a) had also the same frequency of 
reporting. Even lower reporting proportion at a level of 18.2% had the following items: 
interim analyses and stopping guidelines (Item 7b), blinding with description of who was 
blinded and how (Item 11a) and reason for trial end or stop (Item 14b). Implementation 
(Item 10) and similarity of interventions (Item 11b) had a frequency of reporting equal to 
9.1%. In absolute numbers, they were only reported by 1 out of 11 articles. Results for 
each group and each outcome including effect size and precision (Item 17a) and 
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presentation of absolute and relative effect sizes for binary outcomes (Item 17b) were also 
reported by 1 out of 11 articles. 
Proportions of reporting of the 37 items for the pre-CONSORT 2010 and the post-
CONSORT 2010 period are shown in Table3. 
Between pre- and post-CONSORT 2010 period groups, it seems a significant 
improvement over time in reporting objectives (Item 2b, Fisher exact P=0.018<0.05). 
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Table2. Scores of selected  RCT reports using CONSORT 2010 checklist 
Data items RCT1 RCT2 RCT3 RCT4 RCT5 RCT6 RCT7 RCT8 RCT9 RCT10 RCT11 
1a.Title 0 0 0 0 0 0 1 1 0 1 0 
1b.Abstract 1 1 1 1 1 1 1 1 1 1 1 
2a.Background 1 1 1 1 1 1 1 1 1 1 1 
2b.Objectives 1 1 1 1 1 1 1 1 1 0 0 
3a.Trial design 1 1 1 1 1 0 1 1 0 1 1 
3b.Changes to 
methods 1 1 0 0 0 0 1 1 1 1 0 
4a.Eligibility 
criteria 1 1 1 1 1 1 1 1 1 1 1 
4b.Settings 0 1 1 1 1 1 1 1 1 1 1 
5.Interventions 1 1 1 1 1 1 1 1 1 0 1 
6a.Outcomes 1 1 1 0 1 1 1 1 0 1 1 
6b.Changes to 
outcomes 0 0 0 0 0 0 0 0 0 0 0 
7a.Sample size 1 1 1 1 1 1 1 1 1 1 1 
7b.Interim 
analysis 0 0 0 0 0 0 1 0 0 1 0 
8a.Allocation 
sequence 0 0 0 1 0 0 1 0 0 1 0 
8b.Type of 
randomisation 1 1 1 0 1 1 1 0 0 1 1 
9.Allocation 
concealment 0 1 1 0 0 1 1 0 0 1 1 
10.Implementation 0 0 0 0 0 0 0 0 0 1 0 
11a.Blinding 0 0 0 0 0 0 0 1 0 1 0 
11b.Similarity of 
interventions 0 0 0 0 0 0 0 1 0 0 0 
12a.Statistical 
methods 1 0 1 0 1 0 1 1 0 1 1 
12b.Additional 
analyses 1 1 1 0 1 0 1 1 0 1 0 
13a.Participant 
flow 1 1 1 1 1 1 1 1 1 1 1 
13b.Losses and 
exclusions 1 1 1 1 1 1 1 1 0 0 0 
14a.Recruitment 1 0 0 0 0 0 1 0 1 1 0 
14b.Trial end 1 0 0 0 0 0 0 0 0 1 0 
15.Baseline data 1 1 1 1 1 1 1 1 1 1 1 
16.Numbers 
analysed 1 1 1 1 1 1 1 1 1 1 1 
17a.Outcomes and 
estimations 0 0 0 0 0 0 1 0 0 0 0 
17b.Binary 
outcomes 0 0 0 0 0 0 1 0 0 0 0 
18.Ancillary 
analyses 0 1 1 1 1 0 1 1 0 0 0 
19.Harms 1 1 1 1 1 1 1 1 1 1 1 
20.Limitations 1 1 0 1 1 1 1 1 1 1 1 
21.Generalisability 1 1 1 1 1 1 1 1 1 1 1 
22.Interpretation 1 1 0 1 1 1 1 1 1 1 1 
23.Registration 1 1 1 0 0 1 1 1 0 0 1 
24.Protocol 0 0 0 0 0 0 0 0 0 0 0 
25.Funding 1 1 1 1 1 1 1 1 1 1 1 
Total score 24 24 22 19 22 20 31 26 17 27 20 
CONSORT: Consolidated Standards of Reporting Trials; RCT: Randomized Controlled Trial 
RCT numbers correspond to the rank of the articles included in the analysis list (References); RCT10 and  
RCT11 were published in 2005 while RCT1- RCT9 were published after 2010. 
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Table3. Proportion of reporting of 37 data items in a total of 11 RCTs on anti-TNF agents in ulcerative 
colitis by publication period from 2005 to 2015 ( post- ,  pre- CONSORT 2010 and combined) 









1a.Title 27,3% (n=3) 50%  (n=1) 22,2%  (n=2) 0.345 
1b.Abstract 100%  (n=11)  100%  (n=2) 100%  (n=9) - 
2a.Background 100%  (n=11) 100%  (n=2) 100%  (n=9)  - 
2b.Objectives 81,8%  (n=9) 0%  (n=0) 100%  (n=9) 0.018 
3a.Trial design 81,8%  (n=9) 100%  (n=2) 77,8%  (n=7) 1 
3b.Changes to 
methods 
54,5 % (n=6) 50%  (n=1) 55,6%  (n=5) 1 
4a.Eligibility criteria 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
4b.Settings 90,9%  (n=10) 100%  (n=2) 88,9%  (n=8) 1 
5.Interventions 90,9%  (n=10) 50%  (n=1) 100%  (n=9) 0.182 
6a.Outcomes 81,8%  (n=9) 100%  (n=2) 77,8%  (n=7) 1 
6b.Changes to 
outcomes 
0%  (n=0) 0%  (n=0) 0%  (n=0) - 
7a.Sample size 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
7b.Interim analysis 18,2%  (n=2) 50%  (n=1) 11,1%  (n=1) 0.345 
8a.Allocation 
sequence 
27,3% (n=3) 50%  (n=1) 22,2%  (n=2) 0.491 
8b.Type of 
randomisation 
72,7%  (n=8) 100%  (n=2) 66,7%  (n=6) 1 
9.Allocation 
concealment 
54,5%  (n=6) 100%  (n=2) 44,4%   (n=4) 0.455 
10.Implementation 9,1%  (n=1) 50%  (n=1) 0%  (n=0) 0.182 
11a.Blinding 18,2%  (n=2) 50%  (n=1) 11,1%  (n=1) 0.345 
11b.Similarity of 
interventions 
9,1%  (n=1) 0%  (n=0) 11,1%  (n=1) 1 
12a.Statistical 
methods 
63,6%  (n=7) 100%  (n=2) 55,6%  (n=5) 0.491 
12b.Additional 
analyses 
63,6%  (n=7) 50%  (n=1) 66,7%  (n=6) 1 
13a.Participant flow 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
13b.Losses and 
exclusions 
72,7%  (n=8) 0%  (n=0) 88,9%  (n=8) 0.055 
14a.Recruitment 36,4%  (n=4) 50%  (n=1) 33,3%  (n=3) 1 
14b.Trial end 18,2%  (n=2) 50%  (n=1) 11,1%  (n=1) 0.345 
15.Baseline data 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
16.Numbers analysed 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
17a.Outcomes and 
estimations 
9,1%  (n=1) 0%  (n=0) 11,1%  (n=1) 1 
17b.Binary outcomes 9,1%  (n=1) 0%  (n=0) 11,1%  (n=1) 1 
18.Ancillary analyses 54,5%  (n=6) 0%  (n=0) 66,7%  (n=6) 0.182 
19.Harms 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
20.Limitations 90,9%  (n=10) 100%  (n=2) 88,9%  (n=8) 1 
21.Generalisability 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
22.Interpretation 90,9%  (n=10) 100%  (n=2) 88,9%  (n=8) 1 
23.Registration 63,6%  (n=7) 50%  (n=1) 66,7%  (n=6) 1 
24.Protocol 0%  (n=0) 0%  (n=0) 0%  (n=0) - 
25.Funding 100%  (n=11) 100%  (n=2) 100%  (n=9) - 
RCT: Randomized Controlled Trial ; TNF: Tumor Necrosis Factor ; CONSORT: Consolidated Standards of 
Reporting Trials  
P-values obtained from Fisher exact tests between frequency of reporting an item and publication period 
group (pre- and post-CONSORT 2010 period group). 
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In this era even more biologic agents are being developed and tested against immune-
mediated diseases in several fields of medicine(22, 23). This original study, applying 
concrete methods and eligibility criteria, selected 11 reports of RCTs for anti-TNF agents 
in ulcerative colitis, covering a publication period of the last decade. Its aim is to assess 
the reporting quality of these RCTs using the revised CONSORT 2010 statement and 
examine the CONSORT 2010 effect on improving the reporting quality over time. 
It is demonstrated through the results that, the overall reporting quality of all RCTs 
selected, indicated by the total CONSORT 2010 score, stands on an average level without 
significant differences between pre- and post-CONSORT 2010 publication periods. 
Additionally, reporting items are documented in a wide range of frequencies across the 
sum of articles. Of the most frequently reported items are abstract and introduction items, 
trial design, participants, interventions, sample size, Intention-to-treat analysis, harms and 
discussion items. In contrast, identification as a RCT in the title, changes to outcomes, 
interim analyses, allocation sequence generation, implementation, blinding, trial end, 
outcomes and protocol are really problematic in reporting. CONSORT 2010 shows also 
significant effect on reporting the objectives item over time. 
Although all items of the checklist contribute to the reporting quality, some of them can 
be considered as key methodological items, because they help the reader to assess 
potential sources of bias and consequently the validity of RCT. Allocation concealment 
and randomization implementation, blinding and Intention-to-treat analysis are critical in 
avoiding selection bias, ascertainment and performance, attrition bias respectively(14, 24, 
25). As a result, inadequate or even poor reporting of randomization, blinding and 
implementation, as in this study,  makes the methodological assessment of the RCT 
problematic. Of course, it is declared that, this study does not aim to assess the 
methodological quality of RCTs and that intransparent reporting of an item does not 
necessarily mean that the relative procedure has not been properly conducted. 
Extremely impressive is the really poor reporting of outcomes and estimations items. 
Only one out of the 11 RCT reports presented the outcomes according to the 
recommendations of the CONSORT 2010 statement, providing measures of effect size 
and its precision. It is obvious that, intransparence or lack in outcomes reporting creates 
difficulties in assessing the real treatment effect and drawing credible conclusions. 
Inadequate trial registration and poor protocol reporting, as presented in the results, could 
also generate selective outcome reporting bias(14). 
There are several published studies that assess the reporting quality of RCTs using 
CONSORT statement in different subspecialties of medicine(16, 17, 19, 26). Inadequate 
reporting of key methodological items such as blinding, randomization, Intention-to-treat 
principle is a common characteristic across these studies. 
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Ji-Lin Wang et Al., in a study published in 2011, assessed the methodological reporting 
quality of RCTs in major hepato-gastroenterology journals in 1998 and 2008 using the 
CONSORT statement(21). They concluded in significant improvement in reporting 
several methodological items underlying the significance of CONSORT statement. Other 
items were badly reported though. 
In this study assessing the reporting quality of RCTs on anti-TNF agents in ulcerative 
colitis during the last10 years, conclusions about CONSORT 2010 effect on improving 
the reporting quality are not considered as credible. The reason is the small size of pre- 
and post-CONSORT 2010 publication period groups (9 articles are included in the post-
CONSORT 2010 group and only 2 in the pre-CONSORT 2010 group) and especially the 
disproportionally small size of the pre-CONSORT 2010 group. 
Moreover, this study has further limitations. First of all, the assessment of RCT reports, 
according to the CONSORT statement, was conducted by only one person, the author. 
Review by a second person would probably reduce the subjective factor. Secondly, the 
search was restricted in only 2 databases: Pubmed and Cochrane CENTRAL. Another 
limitation is that eligible were only articles published in English language. Although, 
CONSORT 2010 statement is designed mainly for typical RCTs with two study arms, 
trials with 3 or 4 study groups were eligible. In contrast to these limitations, strength of  
this study is that all items of the last revised 2010 CONSORT checklist were used in the 
assessment process. 
In conclusion, RCTs on anti-TNF agents in ulcerative colitis published in the last decade 
have suboptimal reporting quality, as assessed using CONSORT 2010 statement. 
Although several items are well reported, poor reporting of some critical items makes the 
reports susceptible to bias, reduces their value to generate medical evidence and limits 
health care decision making and policy designing. Improvement in the reporting quality 
of RCTs in hepato-gastroenterology has been made and the role of CONSORT is crucial 
in this domain(21). As new biologic agents are going to be added in the therapeutic 
armamentarium of ulcerative colitis(22), stronger adherence of their RCT reports to 
CONSORT statement is necessary in order to assess effectively their validity and draw 
credible conclusions. Wider endorsement of CONSORT statement by medical journals 
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7. Appendix  
CONSORT 2010 checklist of information to include when reporting a randomised trial* Downloaded from 
the site www.consort-statement.org in July 2015 
Section/Topic 
Item 




Title and abstract 
 1a Identification as a randomised trial in the title  
1b Structured summary of trial design, methods, results, and 





2a Scientific background and explanation of rationale  
2b Specific objectives or hypotheses  
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including 
allocation ratio 
 
3b Important changes to methods after trial commencement (such as 
eligibility criteria), with reasons 
 
Participants 4a Eligibility criteria for participants  
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufficient details to allow 
replication, including how and when they were actually 
administered 
 
Outcomes 6a Completely defined pre-specified primary and secondary outcome 
measures, including how and when they were assessed 
 
6b Any changes to trial outcomes after the trial commenced, with 
reasons 
 
Sample size 7a How sample size was determined  
7b When applicable, explanation of any interim analyses and stopping 
guidelines 
 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence  
8b Type of randomisation; details of any restriction (such as blocking 
and block size) 
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9 Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any steps 




10 Who generated the random allocation sequence, who enrolled 
participants, and who assigned participants to interventions 
 
Blinding 11a If done, who was blinded after assignment to interventions (for 
example, participants, care providers, those assessing outcomes) 
and how 
 
11b If relevant, description of the similarity of interventions  
Statistical 
methods 
12a Statistical methods used to compare groups for primary and 
secondary outcomes 
 





(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who were randomly 
assigned, received intended treatment, and were analysed for the 
primary outcome 
 
13b For each group, losses and exclusions after randomisation, together 
with reasons 
 
Recruitment 14a Dates defining the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
Baseline data 15 A table showing baseline demographic and clinical characteristics 




16 For each group, number of participants (denominator) included in 





17a For each primary and secondary outcome, results for each group, 
and the estimated effect size and its precision (such as 95% 
confidence interval) 
 
17b For binary outcomes, presentation of both absolute and relative 




18 Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified from 
exploratory 
 
Harms 19 All important harms or unintended effects in each group (for 
specific guidance see CONSORT for harms) 
 
Discussion 
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Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, 
and, if relevant, multiplicity of analyses 
 
Generalisability 21 Generalisability (external validity, applicability) of the trial 
findings 
 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, 
and considering other relevant evidence 
 
Other information  
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), 
role of funders 
 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and 
Elaboration for important clarifications on all the items. If relevant, we also recommend reading 
CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-
pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are 
forthcoming: for those and for up to date references relevant to this checklist, see www.consort-
statement.org 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:07 EET - 137.108.70.7
